Walter Nahm, MD, Ph.D., Inc
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nahm, Walter
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
NCT04800562: A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

Terminated
2
4
US
PCS499, placebo
Processa Pharmaceuticals
Necrobiosis Lipoidica
02/23
04/23
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23

Download Options